ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020â2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2.
ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-lambda1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-lambda as an effective therapeutic agent against SARS-CoV-2.
ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-lambda1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-lambda as an effective therapeutic agent against SARS-CoV-2.
ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-lambda1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-lambda as an effective therapeutic agent against SARS-CoV-2.
ABSTRACT
The antiviral activity of recombinant human IFN-lambda type 1 (IFNλ-1) against culture strain of SARS-CoV-2 virus was determined by infecting a highly sensitive VeroE6 coronavirus cell culture after preincubation test (the cell monolayer was incubated with 4-fold dilutions of IFNλ-1 in a concentration range of 0.16-42,500 ng/ml in a culture medium for 12 h at 37°C) and without preincubation (simultaneous addition of different concentrations of IFNλ-1 and SARS-CoV-2 infection in a dose of 102 TCID50). The created recombinant human IFNλ-1 demonstrated obvious antiviral activity against SARS-CoV-2 virus in vitro. In the tests with and without preincubation, IFNλ-1 exhibited significant activity, although somewhat lower in variant with simultaneous addition of IFNλ-1 and virus to the cell culture. It should be noted that the antiviral effect of IFNλ-1 was observed in a wide range of concentrations.
Subject(s)
Antiviral Agents/pharmacology , Interferons/pharmacology , Recombinant Proteins/pharmacology , SARS-CoV-2/drug effects , Viral Load/drug effects , Virus Replication/drug effects , Animals , Antiviral Agents/isolation & purification , COVID-19/virology , Chlorocebus aethiops , Cloning, Molecular , Escherichia coli/genetics , Escherichia coli/metabolism , Gene Expression , Humans , Interferons/biosynthesis , Interferons/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/isolation & purification , SARS-CoV-2/genetics , SARS-CoV-2/growth & development , Vero Cells , Viral Load/genetics , COVID-19 Drug TreatmentABSTRACT
Despite significant advances in the pharmaceutical industry, there are currently no effective universal drugs for the treatment of viral infections. This fact became especially evident during the COVID-19 pandemic. One type of the potential antiviral agents are interferons, which have already proved to be effective for the treatment of diseases caused by viruses. This article discusses the possibility of using recombinant human interferon lambda-1 and its pegylated form for the treatment of infection caused by SARS-CoV-2. Experiments on a Vero E6 cell culture showed that a pharmaceutical substance based on recombinant human interferon lambda-1 immobilized on PEG 1500 by electron-beam pegylation exhibited significant antiviral activity with high therapeutic index against SARS-CoV-2 and produced low cytotoxic effect on Vero E6 cells. It is concluded that this substance can be used to create a drug for the treatment of viral infection caused by SARS-CoV-2.